rs28941778
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM2PM5PP3PP5_Very_Strong
The NM_024426.6(WT1):c.1405G>T(p.Asp469Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D469G) has been classified as Pathogenic.
Frequency
Consequence
NM_024426.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
WT1 | NM_024426.6 | c.1405G>T | p.Asp469Tyr | missense_variant | 9/10 | ENST00000452863.10 | NP_077744.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
WT1 | ENST00000452863.10 | c.1405G>T | p.Asp469Tyr | missense_variant | 9/10 | 1 | NM_024426.6 | ENSP00000415516 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Drash syndrome;C3151568:Nephrotic syndrome, type 4 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Centre for Translational Omics - GOSgene, University College London | Mar 16, 2018 | - - |
WT1-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 12, 2023 | The WT1 c.1390G>T variant is predicted to result in the amino acid substitution p.Asp464Tyr. This variant has been reported in an individual with early onset Denys Drash syndrome (reported as D396Y, Little et al. 2000. PubMed ID: 10738002). This variant has also been reported as a de novo variant in an individual with WT1-related nephropathy and in an individual from a cohort of pediatric patients with segmental glomerulosclerosis and focal segmental glomerulosclerosis (SRNS/FSGS) with end-stage renal disease (ESRD)(Table S4, Mestek-Boukhibar et al. 2018. PubMed ID: 30049826; reported as D469Y, Supplementary Table S2, Park et al. 2020. PubMed ID: 32604935). Other variants affecting the same amino acid (Asp464) have been reported in individuals with Denys Drash Syndrome/Nephrotic Syndrome (reported as Asp396His, Hakan et al. 2012. PubMed ID: 22876585; reported as Asp396Gly and Asp396Asn, Pelletier et al. 1991. PubMed ID: 1655284; reported as D396N, Table 3, Li et al. 2010. PubMed ID: 20442690). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Taken together, the WT1 c.1390G>T (p.Asp464Tyr) variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at